Recombinant Full Length Human Tumor Necrosis Factor Ligand Superfamily Member 14(Tnfsf14) Protein, His-Tagged
Cat.No. : | RFL23757HF |
Product Overview : | Recombinant Full Length Human Tumor necrosis factor ligand superfamily member 14(TNFSF14) Protein (O43557) (1-240aa), fused to N-terminal His tag, was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
- Download
Source : | E.coli expression system |
Species : | Homo sapiens (Human) |
Tag : | His |
Form : | Lyophilized powder |
Protein length : | Full Length (1-240) |
AA Sequence : | MEESVVRPSVFVVDGQTDIPFTRLG RSHRRQSCSVARVGLGLLLLLMGAG LAVQGWFLLQLHWRLGEMVTRLPDG PAGSWEQLIQERRSHEVNPAAHLTG ANSSLTGSGGPLLWETQLGLAFLRG LSYHDGALVVTKAGYYYIYSKVQLG GVGCPLGLASTITHGLYKRTPRYPE ELELLVSQQSPCGRATSSSRVWWDS SFLGGVVHLEAGEKVVVRVLDERLV RLRDGTRSYFGAFMV |
Purity : | Greater than 90% as determined by SDS-PAGE. |
Applications : | SDS-PAGE |
Notes : | Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week. |
Storage : | Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
Storage Buffer : | Tris/PBS-based buffer, 6% Trehalose, pH 8.0 |
Reconstitution : | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference. |
Gene Name : | TNFSF14 |
Synonyms : | TNFSF14; HVEML; LIGHT; UNQ391/PRO726; Tumor necrosis factor ligand superfamily member 14; Herpes virus entry mediator ligand; HVEM-L; Herpesvirus entry mediator ligand; CD antigen CD258 |
UniProt ID : | O43557 |
Gene Name : | TNFSF14 |
Synonyms : | TNFSF14; HVEML; LIGHT; UNQ391/PRO726; Tumor necrosis factor ligand superfamily member 14; Herpes virus entry mediator ligand; HVEM-L; Herpesvirus entry mediator ligand; CD antigen CD258 |
UniProt ID : | O43557 |
Products Types
◆ Recombinant Protein | ||
TNFSF14-4501H | Recombinant Human TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
Tnfsf14-6555M | Recombinant Mouse Tnfsf14 Protein, Myc/DDK-tagged | +Inquiry |
TNFSF14-1324H | Acitve Recombinant Human TNFSF14 protein(Asp74-Val240), rFc-tagged | +Inquiry |
TNFSF14-150H | Recombinant Human TNFSF14 Protein, His-tagged | +Inquiry |
TNFSF14-783C | Recombinant Cynomolgus Monkey TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
TNFSF14-891HCL | Recombinant Human TNFSF14 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThe extended longevity of results gave us the confidence to delve deeper into complex biological processes.
It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.
The ability to obtain enduring results positively influenced the depth of our investigations.
Q&As (7)
Ask a questionTNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.
While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.
TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.
TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.
TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.
TNFSF14 has been in pre-clinical development for over a decade.
TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.
Ask a Question for All TNFSF14 Products
Required fields are marked with *
My Review for All TNFSF14 Products
Required fields are marked with *
Inquiry Basket